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Introduction 
Performance criteria for bioanalytical analysis of dioxins in food were previously developed by a consortium of 
scientists experienced with the assay, including the two companies that commercialized the CALUX bioassay. 
Criteria were presented at the Dioxin 2001 conference in Gyeongju, Korea (1) and later on adopted by the EU in a 
document dealing with performance criteria for both the HRGC/HRMS confirmatory method and screening assays 
(2,3). Minor changes were introduced in updates (4,5), but recently it was decided to reevaluate the criteria based on 
gained experience of a number of National Reference Laboratories and the European Union Reference Laboratory. 
The present paper describes the major issues discussed by the working group and the proposed revisions. 
 
Bioanalytical methods generate qualitative or semi-quantitative results 
Exposure of cells to PCDD/Fs or dl-PCBs results in a concentration dependant increase of the response. However, 
the newly proposed requirements stress the fact that the main purpose of the test is screening in order to obtain a 
qualitative result. This will be achieved by comparison of the test result with a certain cut-off value. This is in line 
with the IUPAC definition of quantitative analysis, stating that quantitative analysis requires the identification 
(qualification) of the analytes for which numerical estimates are given (6). As discussed below, this is not 
necessarily the case for the CALUX-assay. Also the new EU guidelines for the validation of screening methods for 
residues of veterinary medicines clearly define the nature of results from bioanalytical screening as qualitative or 
semi-quantitative, the latter primarily intended for guidance of the confirmatory method. 
 
Indicative levels from bioanalytical screening methods are best expressed in bioanalytical equivalents (BEQs)  
An indicative level in the sample may be calculated but it should be clear that this semi-quantitative figure results 
from screening and not from HRGC/HRMS. This is best achieved by expressing the result in BEQs rather than 
TEQs. When a standard deviation on the indicative level is given, this should represent at least a triplicate analysis, 
including extraction and clean-up. 
 PCDD/Fs and dl-PCBs actually refer to a mixture of compounds with similar toxicological effects but different 
potencies. In practice this means that the effects are additive but that the actual cumulative effect depends on the 
relative potencies of the compounds present in the mixture. The TEQ-principle was introduced to deal with the 
differences in toxic potencies of the various congeners. Based on in vivo and in vitro studies it was decided whether 
congeners should obtain a so-called TEF value and if so, what this TEF-value should be. The decision to assign a 
TEF value was not simply based on the ability of compounds to bind to the Ah-receptor (AhR) and/or induce 
dioxin-like gene expression, since this would also apply for many AhR-active polycyclic aromatic hydrocarbons 
(PAHs) and naturally occurring compounds present in many fruits and vegetables, but the ability of the congener to 
produce a common set of AhR-dependent toxic effects. A second important feature of the compounds assigned TEF 
values (i.e. PCDD/Fs and dl-PCBs) is their relative resistance to metabolic degradation, thus resulting in their 
accumulation in humans and animals. Only 7 PCDDs and 10 PCDFs, as well as 12 dioxin-like PCBs were therefore 
included. While other candidate compounds and compound classes (e.g., brominated and mixed halogenated 
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dioxins/furans and polychlorinated naphthalenes) are being considered for inclusion in the TEF toxicity scheme, 
they have not yet been assigned TEF-values.  
 In practice the current CALUX bioassays are to some extent selective towards these different classes of 
compounds. First of all, and very crucial for routine application, the test applies a clean-up with a sulfuric acid-silica 
column, which will remove many of the non-dioxin-like AhR agonists. In some cases an additional clean-up over 
activated carbon is used, intended to separate dl-PCBs from PCDD/Fs but also removing other undesired AhR active 
compounds. Secondly, the cells used for the assays are to some extent able to inactivate certain compounds by 
active metabolism. Nevertheless, in routine testing, certain types of products frequently show an elevated response 
that cannot be assigned to PCDD/Fs or dl-PCBs included in the TEQ principle. It cannot be excluded that this 
response is due to compounds that do not produce dioxin-like adverse effects and an expression of the result in 
TEQs may suggest otherwise. Nevertheless, the detection of potential novel risks is an important advantage of the 
use of a combined bioanalytical and chemo-analytical approach and follow-up of false-positive test results is 
recommended. 
 Another important issue is the way in which the TEFs were assigned. While all available data on relative 
potencies were evaluated, there was a clear emphasis on those values directly associated with the production of toxic 
effects in animals or humans, if available. Such studies would include potential differences in pharmacokinetics but 
also evaluate the actual adverse effects beyond the initial steps of the mechanism of action of these compounds (i.e. 
the binding to the AhR and the subsequent change in gene expression, protein levels or enzymatic activities). The 
relative potencies derived in various studies may show a wide range and the assigned TEF-values are in practice 
weighted factors. Although there is a clear correlation between the assigned TEF-values and the relative response, 
expressed as a relative potencies (REPs), in the bioassays, there is not an exact 1 to 1 relationship. Also based on the 
deviation between REPs and TEFs, the result of a bioanalytical method can only provide an estimation of the total 
TEQ of a sample that would be derived from HRGC/HRMS analysis, where the levels of the individual congeners 
are determined, multiplied by the assigned TEF-value and summed.  
 
Bioassay calibration curve and working range 
The concentration-dependent production of the AhR-inducible enzyme luciferase (in the CALUX bioassay) follows 
the shape of a sigmoid-like curve, which can be characterized by a maximum response (Rmax), an EC50, being the 
concentration resulting in a half-maximal response, and a slope parameter at the EC50 value. In dose-response 
curves, residuals are not equal at all concentrations and therefore it seems justified to apply a weighted least squares 
(WLS) regression to fit a 4-parametric sigmoid Hill function. It has been shown, however, that in particular in the 
lower part of the curve even this fit is far from ideal. In WLS regression, a coefficient of determination (R2) close to 
1 does not guarantee a satisfactory regressive fit. A better curve fit is obtained when instead of optimizing the R2, 
the sum of squared residuals (SSR) is minimized. 
 For routine testing it is important to know the concentration range that leads to a trustworthy result. It is clear 
that at low concentrations the influence of an unspecific background response on the results is strong, and a small 
variation in the response leads to large variations in the estimated level in the sample. The latter is also true for a 
response close to the maximum response (Rmax). For this reason, it seems impossible to determine an LOD or LOQ 
solely based on the mean response and SD obtained with the solvent (DMSO). If determined at all, it should be set 
at a sample level showing a significantly elevated response in comparison with the non-contaminated sample.  
 Standard solutions and sample extracts should be tested at least in duplicate wells. When using duplicates, a 
standard solution or a control extract tested in 4 to 6 wells distributed across the plate should produce a response or 
concentration (only possible in the working range) with a CV<15%. 
 When calculating the concentrations from a TCDD calibration curve, values at the lower and higher end of the 
curve will show a high variation (CV). The working range is the area where this CV is smaller than 15%. The lower 
end of the working range (reporting limit) must further be set significantly (at least by a factor of three) above the 
procedure blanks. The upper end of the working range is usually represented by the EC70 value (70% of maximal 
effective concentration), but lower if the CV is higher than 15% in this range. The working range should be 
established during validation. Cut-off values (see below) must be within the working range.  
The question that remains is what to do with samples with a test response outside the working range. 
Previously, the performance criteria included the obligation to dilute extracts to obtain a more reliable estimate. In 
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practice, samples with a response lower than the working range will be negative (below cut-off) and require no 
further investigation. Samples showing a test response above the working range are possible candidates for high 
levels of PCDD/Fs and/or dl-PCBs and should be analyzed by HRGC/HRMS as soon as possible. Additional 
investigations to obtain a better estimate of the level of a suspected sample should certainly not delay the 
confirmatory analysis. 
 
Recovery, reproducibility and repeatability 
Contrary to HRGC/HRMS, bioanalytical methods cannot control their extraction and clean-up process by including 
internal standards. This makes the assay potentially vulnerable to variations in extraction efficiency and the recovery 
of the compounds of interest. However, extensive analysis has revealed that the extraction and clean-up over acidic 
silica are processes with a high and reproducible recovery. More critical may be the evaporation of the final extract. 
In order to obtain a view on the real recovery, final extracts should also be examined by HRGC/HRMS as part of the 
validation studies. 
 In current legislation, the requirement for the precision or relative standard deviation obtained under 
reproducibility conditions (RSDR) is set at <30%. Since this has serious consequences for the cut-off value (see 
below), it was decided to reduce this to 25%. In addition an RSDr for repeatability was set to <20%.  
 
Determination of suitable cut-off values for checking compliance with maximum and/or action levels  
The most critical issue when applying a screening method is the cut-off value: “When should a sample be 
considered as suspected to be noncompliant and be further examined with a confirmatory method? And what is an 
acceptable fraction of samples that are in fact non-compliant, whereas a compliant measurement has been obtained 
(false-compliant decision)?” Previously, this so-called beta-error was set at 1% for screening methods for PCDD/Fs 
and dl-PCBs, whereas for other food contaminants 5% is common. A beta-error of 1% presents a number of 
difficulties, a very important one being the fact that it is very difficult to evaluate it during validation. Hundreds of 
positive samples of each sample matrix may have to be tested for this purpose. Furthermore, a low conservative cut-
off level may have to be established, resulting in large numbers of false-noncompliant results (see below), making 
the application of any screening method less effective. 
 The latter is also true when discussing whether cut-off values should be based on maximum levels (ML) or 
action levels (AL), the latter being around 2/3 of the ML for most matrices. The current EU strategy on dioxins and 
dl-PCBs is based on three pillars, maximum (ML), action (AL) and target levels (7). MLs were set to regulate 
compliance, whereas ALs were set as “early warning” for elevated levels to identify possible sources for 
contamination. Samples exceeding the AL but not the ML are compliant but may require further action to discover 
the source of the contamination. MLs were set for PCDD/F-TEQ and the sum of PCDD/F- and dl-PCB-TEQs, 
whereas ALs were set separately for PCDD/F-TEQ and dl-PCB-TEQ. MLs have been set according to the principle 
“strict but feasible”. Data on levels in each type of product were collected and MLs were set around the 95-99% 
level, meaning that 1-5% of the samples with the highest levels would be noncompliant. For most sample matrices, 
ALs were set at 2/3 of the ML. The main focus of bioassays is to check compliance of samples, meaning that the 
control of MLs is the main point of interest. It may however be argued that bioassays should also detect most of the 
samples exceeding the AL, but no performance criteria were set for this purpose (see below). 
 For determination of ML-based cut-off values, first the relationship between bioanalytical results (in BEQ) and 
HRGC/HRMS results (in TEQ) has to be established (e.g. by matrix-matched calibration experiments, involving 
reference samples spiked at 0, 0.5x, 1x and 2x maximum level, with 6 repetitions on each level) (8). The 
bioanalytical results should be corrected for blank and recovery. Cut-off values are represented by the lower 
endpoint of the distribution of bioanalytical results (RSDR <25%) corresponding to the HRGC/HRMS decision 
limit, which is based on a 95% level of confidence, implying a false-compliant rate <5%. Figure 1 demonstrates the 
relationship between the cut-off values and the ML including the expanded measurement uncertainty, used as a 
decision limit by HRGC/HRMS. In practice, the cut-off value (in BEQ) may be calculated from three different 
approaches: (1)  use of the lower band of the 95% prediction interval at the HRGC/HRMS decision limit, (2) 
calculation from bioanalytical results (corrected for blank and recovery) of multiple analyses of samples (n>6) 
contaminated at the HRGC/HRMS decision limit, as the lower endpoint of the data distribution at the corresponding  
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Figure 1. Calculation of cut-off values based on a 95% level of confidence implying a false-compliant rate < 5%, 
and a RSDR <25%: 1. from the lower band of the 95% prediction interval at the HRGC/HRMS decision limit, 2. 
from multiple analysis of samples (n>6) contaminated at the HRGC/HRMS decision limit as the lower endpoint of 
the data distribution (represented in the figure by a bell-shaped curve) at the corresponding mean BEQ value. 
 
mean BEQ value, or (3) calculation as mean value of bioanalytical results (in BEQ, corrected for blank and 
recovery) from multiple analysis of samples (n>6) contaminated at 2/3 the level of interest. 
 This cut-off value will in practice be slightly higher than 2/3 of the ML, i.e. for most matrices corresponding to 
the current AL. So, based on both the theoretical considerations and the practical experience it can be concluded that 
cut-off values at 2/3 of the ML are suitable to guarantee a beta-error of less than 5%. In practice, BEQ-based cut-off 
values calculated from the RSDR achieved during validation using a limited number of samples with different 
matrix/congener patterns may be higher than the TEQ-based levels of interest due to a better precision than 
attainable in routine when an unknown spectrum of possible congener patterns has to be controlled. In such cases, 
cut-off values still have to be calculated from an RSDR = 25%, or two-thirds of the level of interest should be 
preferred. 
 In routine, most samples exceeding the AL will be detected as well (9) but no criterion was set for a beta-error 
on the AL. When applying the same beta-error as for the ML, a similar approach as for the ML can be used, 
focusing on a HRGC/HRMS decision limit equal to the AL plus expanded measurement uncertainty. Cut-off values 
would be around 2/3 of the AL. However, this may result in  large numbers of false-noncompliant results, since 
many samples in routine will have levels around this cut-off value. This is exemplified by the recent collection of 
data by EFSA (10), showing that most MLs are around the P95 and that many ALs fall between P75 and P90. A cut-
off value around 2/3 of the AL would correspond to levels around a P75 and require HRGC/HRMS confirmation of 
25% of the samples. As a result, any screening method for PCDD/Fs and dl-PCBs would in theory become useless. 
More importantly, the widespread use of screening methods and subsequent analysis of much larger sample 
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numbers will actually increase the chance of detecting samples with dioxin- and dl-PCB-levels that really present a 
health threat. 
 In practice, levels will be estimated based on a TCDD (or PCB 126) calibration curve and then be corrected for 
blank and recovery based on reference samples. The estimated level is then compared with the cut-off value. Levels 
may also be estimated from a curve based on a set of representative reference samples with levels around the cut-off 
level. In that case, no corrections for blank and recovery are required. This approach also allows the determination 
of the response (in relative light units (RLUs) for the CALUX bioassay) corresponding to the cut-off level, which 
can then be used to qualitatively evaluate the test result of samples (i.e. are they negative or suspected to be 
positive). 
 
To split or not to split  
Current EU-legislation has MLs for PCDD/Fs and the sum of PCDD/Fs and dl-PCBs for each type of product or 
feed ingredient. In addition, there are ALs for both PCDD/Fs and dl-PCBs. Bioanalytical methods in principle detect 
any AhR-agonist present in the sample extract and as such do not discriminate between PCDD/Fs and dl-PCBs. This 
can only be achieved by using an additional clean-up step in order to separate PCDD/Fs and dl-PCBs. Some 
laboratories apply such an additional step based on a column with activated carbon. This is a rather successful 
strategy to compare results directly with the ALs which are set separately for PCDD/Fs and dl-PCBs and with the 
ML separately set for PCDD/F. However, this additional step adds to the complexity of the clean-up and also has 
some consequences for recovery and background response.  
 A major question is how to deal with the cut-off levels when not splitting the extract. It is evident that focusing 
on the ML for the sum of PCDD/Fs and dl-PCBs will result in a high beta-error for samples contaminated with only 
PCDD/Fs, which is true for many incidents. Therefore, a cut-off value based on the ML for PCDD/Fs should be the 
target for screening. Since ALs for dl-PCBs for a number of products are lower than for PCDD/Fs, more samples 
exceeding the AL for dl-PCBs might be missed.  
 
Use of reference samples 
References samples are important for control of procedure and sample matrix blank values and apparent recovery, 
but also for controlling the performance of the test. Furthermore, they may be used for estimating the levels of active 
compounds in the test samples. Ideally, reference samples are incurred materials but in the case of bioanalytical 
methods there is a serious risk that such samples contain unknown AhR-agonists that may give an elevated 
response. Ideally, a material showing a low response in the bioassay is used. Such samples can subsequently be 
fortified at a relatively high level, then be analyzed by HRGC/HRMS and subsequently be diluted with the blank 
starting material to obtain the desired activity levels (e.g. 0.5, 1 and 2x ML). Congener mixtures of PCDD/Fs and dl-
PCBs should be representative for the patterns observed in food and feed, however, since there are many different 
patterns, this seems unfeasible. Most important is that a possible difference between the level based on the TEFs and 
that calculated from using the REPs in the bioassay, will not lead to an underestimation of the level in the test 
sample. In the case of the rat H4IIE-cells it was shown that such CALUX-based levels are for most PCDD/F 
patterns around 60-70%, with the exception of the pattern observed with pentachlorophenol contamination that 
shows a slight activity overestimation. This is due to the high contribution of HpCDD in the sample combined with 
its relatively high response in the test. In the case of dl-PCBs and based on the new TEFs from 2005, PCB 126 
seems by far the most relevant congener. In the rat cells the REP values for this PCB vary between 0.05 and 0.067 
as compared to a TEF of 0.1. So for dl-PCBs the levels in samples will be underestimated by 30-50%, when 
compared to HRGC/HRMS analysis, unless a standard curve of PCB 126 is used instead of TCDD. In H1L6.1c2  
mouse cells, the REPs seem slightly different from those in the rat cells resulting even in an overestimation of the 
levels of PCDD/Fs but an even stronger underestimation of dl-PCBs. In practice it seems unnecessary to produce 
reference samples for each type of product but this should be demonstrated during validation. 
 
Screening and confirmatory methods, just good friends 
It seems obvious that there must be good connection between screening and confirmatory methods. Samples 
showing a suspected response must be analyzed by HRGC/HRMS. However, also part of the samples tested 
compliant should be analyzed by the confirmatory method in order to demonstrate the proper performance of the 
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test. Initially, it is recommended to test 2 to 10% of the negative samples for each type of product (minimum of 20 
per matrix) but this may be decreased in a laboratory with experience over time depending on the results obtained. 
HRGC/HRMS is also important for checking the levels in the standards and reference materials. Overall, it is 
important that a laboratory using the screening method has a good arrangement with a laboratory performing the 
confirmatory method. Laboratories applying the test for control should evaluate the correspondence between results 
obtained by a bioanalytical method and HRGC/HRMS on a regular basis (both compliant and noncompliant results). 
This may result in an adjustment of the cut-off values. At the same time the performance of the test with respect to 
the ALs may be evaluated. 
 Regarding the difference in the principles behind the two types of methods, either based on effects or on the 
structure of the compound, their combined use is also very suitable for the detection of novel risks (11). Screening 
of choline chloride, a widely used feed ingredient, resulted in the discovery of a contamination with brominated 
flame retardants and bromodioxins (PBDD/PBDFs) (12). Initially the positive test result could not be confirmed by 
HRGC/HRMS but follow-up on this “false-positive” result led to the discovery of the contamination. Although not 
included in the legislation, brominated dioxins are well-known to be equitoxic to their chlorinated counterparts and 
it is expected that TEFs will be assigned as experimental potency results are obtained. This example demonstrates 
that routine screening may yield false-noncompliant results but that a follow-up on the compounds responsible for 
this result may reveal novel risks. 
 It is also important to realize that confirmatory methods also allow determination of levels of PCDD/F and 
dioxin-like PCBs reliably in the range of low background levels. This is important in order to follow time trends in 
levels, for performing exposure assessment of a population and to build a database for possible re-evaluation of 
action and maximum levels and derivation of target levels over time. As a result, both screening and confirmatory 
methods have advantages and limitations. However, their complementary use enables to achieve the various goals 
and objectives of feed and food analysis. 
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